Delivering silence: Advancements in developing siRNA therapeutics

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 2, 2008, Pages 217-224

  Novobrantseva, Tatiana I ^a   Akinc, Akin ^a   Borodovsky, Anna ^a   De Fougerolles, Antonin ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Clinical trials; Delivery systems; Gene silencing; RNA interference; RNAi; siRNA; Small interfering RNA

Indexed keywords

AGN 745; AKLI 5; ALN RSV01; APOLIPOPROTEIN B; BEVASIRANIB SODIUM; CHEMOKINE RECEPTOR CCR5; DIOLEOYLPHOSPHATIDYLCHOLINE; IMATINIB; LAMIN A; LAMIN B; LIPOPLEX; LIPOSOME; POLYMER; PROTEIN P53; RTP 801I 14; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDICATION; DRUG TARGETING; ELECTROPORATION; GENE SILENCING; HUMAN; IN VIVO STUDY; NONHUMAN; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; TECHNOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ELECTROPORATION; HUMANS; LIPOSOMES; POLYMERS; RNA, SMALL INTERFERING;

EID: 39549101284     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J: Interfering with disease: A progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6(6):443-453.
2. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Vargeese C et al: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther (2006) 13(3):225-234.
3. de Fougerolles A, Maraganore JM: Discovery and development of RNAi therapeutics. In: Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition. Crooke ST (Ed), CRC Press, London, UK (2007):465-484.
4. Bitko V, Musiyenko A, Shulyayeva O, Barik S: Inhibition of respiratory viruses by nasally administered siRNA. Nat Med (2005) 11(1):50-55. •• Describes a study demonstrating a reduction in viral load of more than 3 orders of magnitude by intranasally administered siRNA in doses as low as 70 μg per animal.
5. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp GL, Zhang X, Matthay MA, Ware LB, Homer RJ, Lee PJ et al: Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med (2006) 12(11):1286-1293.
6. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P, Wishart W et al: siRNA relieves chronic neuropathic pain. Nucleic Acids Res (2004) 32(5):e49.
7. Makimura H, Mizuno TM, Mastaitis JW, Agami R, Mobbs CV: Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci (2002) 3:18.
8. Thakker DR, Natt F, Husken D, Maier R, Muller M, van der Putten H, Hoyer D, Cryan JF: Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA (2004) 101(49):17270-17275.
9. Thakker DR, Natt F, Hüsken D, van der Putten H, Maier R, Hoyer D, Cryan JF: siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry (2005) 10(8):782-789.
10. Hickerson RP, Smith FJ, Reeves RE, Contag CH, Leake D, Leachman SA, Milstone LM, McLean WH, Kaspar RL: Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol (2007): epublished ahead of print. DOI:10.1038/sj.jid.5701060.
11. Wang Q, Ilves H, Chu P, Contag CH, Leake D, Johnston BH, Kaspar RL: Delivery and inhibition of reporter genes by small interfering RNAs in a mouse skin model. J Invest Dermatol (2007) 127(11):2577-2584.
12. Aigner A: Gene silencing through RNA interference (RNAi) in vivo: Strategies based on the direct application of siRNAs. J Biotechnol (2006) 124(1):12-25.
13. Bumcrot D, Manoharan M, Koteliansky V, Sah DW: RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol (2006) 2(12):711-719.
14. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW: Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res (1993) 53(16):3765-3770.
15. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD et al: RNAi-mediated gene silencing in non-human primates. Nature (2006) 441(7089):111-114. •• Describes a study demonstrating the silencing of an endogenous liver gene in non-human primates at a single dose as low as 1 mg/kg using a liposomal delivery system.
16. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N et al: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 23(8):1002-1007.
17. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC et al: Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 193(12):1650-1657.
18. Yokota T, Iijima S, Kubodera T, Ishii K, Katakai Y, Ageyama N, Chen Y, Lee YJ, Unno T, Nishina K, Iwasaki Y et al: Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C. Biochem Biophys Res Commun (2007) 361(2):294-300.
19. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 65(15):6910-6918. •• Describes the use of a non-cationic, neutral lipid-based delivery system to silence a tumor target in an orthotopic mouse model of ovarian cancer.
20. Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM et al: Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 12(16):4916-4924.
21. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM, Lieberman J: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2006) 439(7072):89-94.
22. Zhang Y, Cristofaro P, Silbermann R, Pusch O, Boden D, Konkin T, Hovanesian V, Monfils PR, Resnick M, Moss SF, Ramratnam B: Engineering mucosal RNA interference in vivo. Mol Ther (2006) 14(3):336-342.
23. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH: Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med (2007) 7(2):47-55.
24. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432(7014):173-178.
25. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T et al: Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol (2007) 25(10):1149-1157. •• Elucidates the mechanism of in vivo delivery for cholesterol-conjugated siRNAs by lipoprotein particle association, and identifies the receptors required.
26. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M et al: Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA (2007) 104(43):17204-17209.
27. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N: Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 448(7149):39-43.
28. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M: Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA (2007) 104(10):4095-4100. • Describes the use of protamine-antibody technology to silence immune cells and demonstrates the ability to target activated leukocytes specifically.
29. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA et al: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 23(6):709-717.
30. Meade BR, Dowdy SF: Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev (2007) 59(2-3):134-140.
31. Moschos SA, Williams AE, Lindsay MA: Cell-penetrating-peptide-mediated siRNA lung delivery. Biochem Soc Trans (2007) 35 (Pt 4):807-810.
32. McNamara JO II, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH: Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 24(8):1005-1015. • Describes the cell type-specific, Dicer-dependent silencing by an aptamer-siRNA chimera in vitro and in an in vivo tumor model.
33. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 65(19):8984- 8992.
34. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA (2007) 104(14):5715-5721.
35. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, Hagstrom JE et al: Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA (2007) 104(32):12982- 12987. •• Introduces a novel, endosomally activated membrane-destabilizing polymer conjugate-based approach to in vivo siRNA delivery.
36. Inoue T, Sugimoto M, Sakurai T, Saito R, Futaki N, Hashimoto Y, Honma Y, Arai I, Nakaike S: Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA. J Gene Med (2007) 9(11):994-1001.
37. Matsuda T, Cepko CL: Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci USA (2004) 101(1):16-22.
38. Akaneya Y, Jiang B, Tsumoto T: RNAi-induced gene silencing by local electroporation in targeting brain region. J Neurophysiol (2005) 93(1):594-602.
39. Golzio M, Mazzolini L, Moller P, Rols MP, Teissie J: Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther (2005) 12(3):246-251.
40. Kishida T, Asada H, Gojo S, Ohashi S, Shin-Ya M, Yasutomi K, Terauchi R, Takahashi KA, Kubo T, Imanishi J, Mazda O: Sequence-specific gene silencing in murine muscle induced by electroporation-mediated transfer of short interfering RNA. J Gene Med (2004) 6(1):105-110.
41. Inoue A, Takahashi KA, Mazda O, Terauchi R, Arai Y, Kishida T, Shin-Ya M, Asada H, Morihara T, Tonomura H, Ohashi S et al: Electro-transfer of small interfering RNA ameliorated arthritis in rats. Biochem Biophys Res Commun (2005) 336(3):903-908.
42. Schiffelers RM, Xu J, Storm G, Woodle MC, Scaria PV: Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum (2005) 52(4):1314-1318. • Describes the therapeutic efficacy of the electroporated siRNA in an established model of arthritis.
43. Takabatake Y, Isaka Y, Mizui M, Kawachi H, Shimizu F, Ito T, Hori M, Imai E: Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther (2005) 12(12):965-973.
44. Golzio M, Mazzolini L, Ledoux A, Paganin A, Izard M, Hellaudais L, Bieth A, Pillaire MJ, Cazaux C, Hoffmann JS, Couderc B et al: In vivo gene silencing in solid tumors by targeted electrically-mediated siRNA delivery. Gene Ther (2007) 14(9):752-759.
45. Saito M, Mazda O, Takahashi KA, Arai Y, Kishida T, Shin-Ya M, Inoue A, Tonomura H, Sakao K, Morihara T, Imanishi J et al: Sonoporation- mediated transduction of pDNA/siRNA into joint synovium in vivo. J Orthop Res (2007) 25(10):1308-1316.
46. Tsunoda S, Mazda O, Oda Y, Iida Y, Akabame S, Kishida T, Shin-Ya M, Asada H, Gojo S, Imanishi J, Matsubara H et al: Sonoporation using microbubble BR14 promotes pDNA/siRNA transduction to murine heart. Biochem Biophys Res Commun (2005) 336(1):118-127.
47. Kinoshita M, Hynynen K: Key factors that affect sonoporation efficiency in in vitro settings: The importance of standing wave in sonoporation. Biochem Biophys Res Commun (2007) 359(4):860-865.
48. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T et al: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA (2005) 102(34):12177-12182.
49. Liu N, Ding H, Vanderheyden JL, Zhu Z, Zhang Y: Radiolabeling small RNA with technetium-99m for visualizing cellular delivery and mouse biodistribution. Nucl Med Biol (2007) 34(4):399-404.
50. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME: Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA (2007) 104(39):15549-15554.
51. Medarova Z, Pham W, Farrar C, Petkova V, Moore A: In vivo imaging of siRNA delivery and silencing in tumors. Nat Med (2007) 13(3):372-377. • Describes the combination of several imaging techniques to track siRNA distribution and function in vivo.